Note on figures cited below. Some statistics in this article come from the V12 universe cohort (227,594 BUY filings, period through 2024). Since 2025-01-01 the live out-of-sample BUY universe (28 markets) shows a 52.96 percent win rate and a +8.59 percent mean 90-day return on 20,688 filings. See methodology for the current numbers and the STRATEGY_PROOF block for the frozen audit reference.
Small caps do not whisper, they leave fingerprints.
How to interpret a single filing: who bought, how much, when, and which patterns actually carry signal.
Start with the pillar guide: 如何解读内幕交易：字段解读指南
Insider buying in a €120 million company is rarely a casual hobby. In a €120 billion company, it may be little more than a rounding error with a press release attached. That asymmetry, more than any romance about executives “knowing their business”, is why the small-cap insider edge keeps resurfacing in the literature and in practitioners’ screens.
The claim in this piece is narrow. Buys in small-cap issuers, especially below roughly €200 million in market value, tend to show stronger excess returns over the next 90 trading days than equivalent buys in large caps. The interesting part is not the slogan. It is the decomposition. Once you sort insider purchases by market-cap quintile, what remains of the signal after you strip out the usual suspects, size, illiquidity, neglectedness, and the simple fact that troubled small companies often buy stock because nobody else will?
There is no fresh house dataset attached to this article, so I will not pretend to quote proprietary hit rates or Sharpe ratios. Where numbers from our internal filing database would normally sit, they are marked n/a. The argument instead rests on regulation, market structure, and the accumulated evidence from academic and regulatory sources.
The cleanest explanation is informational frictions. Insider trades are most useful when outside investors know relatively little and when prices do not instantly reflect what insiders reveal. Small caps have both features in abundance.
Large issuers are covered by more analysts, discussed by more institutions, and arbitraged by more systematic capital. Their earnings calls are transcribed, parsed, and compared before the coffee cools. In that setting, an executive purchase may still matter, but it competes with a dense information set. The incremental signal is diluted.
In smaller issuers, the opposite is often true. Coverage can be sparse or absent. Management access is uneven. Financial statements may be technically compliant yet economically thin. Liquidity is lower, which means informed demand moves prices more slowly and more expensively. If a chief executive or chair commits personal capital in that environment, the trade can reveal information that the market was not already pricing efficiently.
This is the oldest and still one of the best explanations. Seyhun’s work on insider trading profitability, and later studies of post-disclosure returns, consistently found stronger abnormal returns where firms are less followed and less liquid. The mechanism is not mystical. It is simply that private information is more valuable when public information is scarce.
Small-cap firms also tend to have wider valuation ranges. A blue-chip consumer staple may oscillate between “slightly expensive” and “moderately expensive”. A €90 million industrial supplier can move from “terminally ignored” to “strategic asset” in one contract cycle. Insider buying in the latter case can therefore point to a larger repricing window.
The second mechanism is market microstructure. In thinly traded names, prices adjust with delay. A disclosed insider purchase can trigger a sequence rather than a single jump: first the filing is noticed, then interpreted, then acted upon by investors who can actually tolerate the liquidity. That creates room for T+90 alpha even if the filing date itself captures some immediate reaction.
This does not mean illiquidity is your friend. Illiquidity can manufacture paper alpha that vanishes in implementation. But it does mean that the informational content of a buy can take longer to diffuse in smaller issuers than in a CAC 40 or Euro Stoxx heavyweight.
In a founder-led or management-heavy cap table, an open-market purchase can be economically meaningful. A €250,000 buy by a director in a €150 million company may represent a serious personal commitment and a visible increase in skin in the game. The same ticket in a mega-cap can be ceremonial, or at least interpreted that way.
This is why serious insider screens usually scale the trade, by salary, prior holdings, free float, or average daily volume, rather than treating all buys as equal. The market often does this informally. It reacts more to purchases that look painful enough to be informative.
A market-cap quintile sort is useful because it forces discipline. “Small cap” is a convenient phrase, but the edge is rarely linear across the size spectrum. The bottom quintile often behaves differently from the second quintile, and both differ materially from the top quintile.
The smallest quintile, often containing micro caps and lower small caps, is where raw insider-buy alpha tends to look strongest. It is also where the data are dirtiest. You get the highest concentration of neglected firms, distressed balance sheets, recapitalisations, governance oddities, and illiquidity artefacts. In other words, the best-looking bucket is also the one most likely to flatter a lazy backtest.
If you run a quintile decomposition properly, Q1 often shows the largest headline T+90 excess return after insider buys. But some of that return can be compensation for bearing ugly risks, and some can be a mirage caused by stale prices and impossible execution. This is the part of the market where one extra filter can improve a strategy more than one extra decimal place.
For many practitioners, the second-smallest quintile is more attractive than the very smallest. These issuers can still be underfollowed enough for insider trades to matter, but they are less likely to be structurally broken. Liquidity is usually better, filings are easier to interpret, and event contamination is somewhat lower.
If your article angle is “under €200M issuers vs blue chips”, this is where the threshold becomes practical rather than philosophical. Depending on the market and period, €200 million often cuts through the lower end of the listed universe in a way that captures neglectedness without diving too deep into the swamp.
In the middle of the cap distribution, insider buying still tends to carry information, but less dramatically. The market already has more external inputs. Analyst coverage is broader. Institutional ownership is higher. The filing is less likely to be the first useful signal in weeks.
The result is usually a lower raw alpha and a faster decay. T+20 may still look respectable. T+90 often remains positive, but the spread versus small caps narrows.
In the largest issuers, insider purchases are not useless. They are simply competing with a more efficient machine. The signal can still matter when the trade is large relative to prior holdings, clustered across several insiders, or timed after a sharp drawdown. But average blue-chip buys tend to produce lower post-disclosure alpha than small-cap buys.
There is also a behavioural reason. Investors are more likely to dismiss large-cap insider buys as symbolic, especially when executive compensation already includes substantial equity. That scepticism is not always wrong.
A market-cap quintile backtest of insider buys sounds straightforward. It is not. Most errors in this area are mundane, which is reassuring if you enjoy preventable mistakes.
Use open-market purchases, not grants, not vesting, not option exercises unless paired with an economically meaningful net buy. The regulatory filing universe contains plenty of activity that looks bullish in a spreadsheet and means almost nothing in practice.
Trade date matters more than filing date for economic interpretation, but filing date matters for implementability. A proper investor-facing backtest should anchor returns from the first tradable point after public disclosure, not from the insider’s execution date. Otherwise you are measuring clairvoyance.
Under MAR Article 19, persons discharging managerial responsibilities and closely associated persons must notify transactions promptly, and issuers must make the information public within three business days. That gives a reasonably tight disclosure clock in Europe, at least on paper.
| Market | Regulator | Rule | Deadline | Notes |
|---|---|---|---|---|
| FR | AMF | MAR Art 19 | T+3 | Directors' dealings disclosed under EU MAR framework; issuer publication required promptly and no later than three business days. |
| US | SEC | Exchange Act Section 16, Form 4 | T+2 | Most insider transactions reported on Form 4 within two business days; implementation differs from EU directors' dealings disclosures. |
This sounds obvious, which is why people still get it wrong. Sort issuers into quintiles using market capitalisation measured immediately before the disclosure event, not current membership, not annual classifications, and certainly not today’s survivors. Otherwise survivorship and migration effects will contaminate the result.
For the article’s framing threshold, “under €200M” should also be measured at or just before the event. A company that later rerates to €800M should not be retroactively promoted into respectability.
Small-cap insider alpha that disappears after controlling for size, value, and momentum was never insider alpha in the first place. At minimum, compare post-event returns to a benchmark matched on market cap and region. Better, run risk-adjusted abnormal returns using standard factors where available.
This matters because insider buys cluster after drawdowns. A beaten-up small cap that rebounds over the next quarter may do so because it was cheap and oversold, not because management bought stock. The insider trade may still be useful, but the decomposition should tell you whether it is additive.
Small-cap filings are often entangled with other events: earnings misses, covenant waivers, placings, strategic reviews, takeover rumours, rescue financings. If you do not isolate these, your quintile result becomes a referendum on corporate stress rather than insider information.
A sensible design excludes or separately tags purchases within a narrow window around earnings announcements, equity raises, merger announcements, and formal restructuring events. Distress buying is a category of its own. Sometimes it works brilliantly. Sometimes it is management trying to reassure the market while the floorboards creak.
A tiny purchase in a tiny stock can still be meaningless. The smaller the issuer, the more important it is to impose a minimum euro value, and ideally a relative threshold as well, such as purchase value divided by prior holdings or annual cash compensation.
This is one reason blue-chip and small-cap strategies should not use identical filters. In large caps, a high absolute threshold may be enough. In small caps, relative significance often matters more.
Thresholds are blunt instruments, but they can still be useful. A sub-€200M issuer bucket often captures the part of the market where analyst coverage drops sharply and liquidity becomes episodic. That is exactly where insider information should have the highest marginal value.
Below €200M, several features tend to coincide:
Put plainly, this is where a director buying shares can still surprise people.
There is also a practical portfolio-construction reason. A simple threshold is easier to monitor than rolling quintiles across multiple exchanges, especially for discretionary investors screening filings in real time. If the objective is to find the strongest part of the signal rather than publish a beautiful academic chart, “under €200M” is a decent first pass.
A €190M company on Euronext Growth and a €190M company on the main market are not the same animal. Nor is a €220M issuer necessarily more efficient than a €180M one. Market structure, free float, governance quality, and country-specific disclosure habits all matter.
Thresholds also drift with inflation and market regimes. A €200M cut in 2016 and the same nominal cut in 2026 do not identify exactly the same economic population. Quintiles solve some of that by defining smallness relative to the contemporaneous universe.
The right way to use the threshold is as an operational shortcut, not a law of nature.
The broad pattern, stronger insider-buy signal in smaller firms, appears in both Europe and the US, but the plumbing differs. In the US, Form 4 data are standardised and heavily mined. In Europe, MAR harmonised the framework, but local market practices and filing presentation still vary. That can slow market digestion and, paradoxically, preserve some of the edge.
France is a good example. The AMF sits within the MAR regime, so the legal timetable is common across the EU. Yet the practical visibility of directors’ dealings still depends on issuer communication, data vendors, and investor attention. In a small French issuer with limited coverage, the filing may remain underappreciated longer than an equivalent US large-cap Form 4.
The academic literature is broad enough to support the central claim, though not every paper uses the exact T+90 and quintile framing. The recurring findings are that insider purchases outperform sales as a signal, and that profitability is stronger in smaller, less-followed, and more difficult-to-value firms.
This is one of the sturdier results in insider-trading research. Sales are noisy. Executives sell for taxes, diversification, school fees, divorce settlements, and the occasional yacht. Purchases are cleaner because people are generally less inclined to buy more of what already dominates their human-capital risk unless they think the price is wrong.
That asymmetry becomes sharper in small caps because the personal and reputational cost of buying into a weak issuer is higher, while the market’s baseline information is poorer.
Studies across markets have linked stronger insider profitability to firms with higher information asymmetry, lower analyst following, and greater valuation uncertainty. Small caps score highly on all three. This is why the small-cap edge should not be interpreted as a pure “size effect”. It is more accurately an opacity effect that often rides inside the size bucket.
Academic studies are excellent at documenting abnormal returns. They are less useful on the grubby details of actually trading the signal in a capacity-constrained portfolio. Bid-ask spreads, borrow constraints, stale pricing, and filing-normalisation errors matter a great deal in the lower-cap universe.
A paper can tell you that insider buys in small firms outperform over the next few months. It cannot guarantee that your fund can buy enough stock, at a reasonable spread, without becoming the market.
Transactions conducted by persons discharging managerial responsibilities, and persons closely associated with them, shall be notified to the issuer or the emission allowance market participant and to the competent authority promptly and no later than three business days after the date of the transaction.
If the objective is to exploit the small-cap insider edge rather than merely admire it, the framework needs to be selective.
One insider buying can matter. Several insiders buying within a short window matters more. Clustered purchases reduce the chance that the signal is idiosyncratic or cosmetic. In small caps, clusters are especially useful because they help distinguish genuine conviction from one director trying to steady the optics.
A €30,000 purchase may be meaningful for one executive and trivial for another. Good screens rank trades by economic significance, such as:
This is where many retail-facing insider trackers fall apart. They count events. Markets price significance.
Exclude or downweight:
The point is not to sanitise the sample until nothing remains. It is to stop the backtest from rewarding paperwork and desperation.
If the edge is strongest at T+90, the strategy should probably not be judged at T+5. Small-cap signals can take time to work because the market notices slowly and trades carefully. But they also decay. Once the repricing has happened, the stock reverts to being a small company with all the usual small-company problems.
A disciplined holding window, perhaps with exits on earnings, capital raises, or extreme reversals, is usually more sensible than indefinite faith in managerial virtue.
The small-cap edge is real enough to be interesting, but not clean enough to be worshipped.
Executives often buy after sharp declines. Sometimes they are right. Sometimes they are averaging down in public. In sub-€200M issuers, where financing risk is more acute, insider buying can be an attempt to reassure creditors, suppliers, and minority shareholders rather than a pure valuation signal.
That does not make the trade worthless. It just means the context matters more than the headline.
A small-cap insider purchase in a well-governed business with credible reporting and aligned ownership is one thing. The same trade in an issuer with serial dilution, promotional language, and board churn is another. The filing format will not tell you this. You have to do the boring part and read.
Even if the alpha is strongest in the lowest-cap quintiles, many institutional investors cannot exploit it at scale. This is one reason the anomaly can persist. The best opportunities may be too small, too illiquid, or too operationally awkward for large pools of capital. Markets are not obliged to eliminate inefficiencies that are expensive to arbitrage.
The practical implication is mildly annoying but useful: the investor most able to exploit the small-cap insider edge may not be the largest or the most sophisticated, but the one with the right size, patience, and tolerance for ugly blotters.
The broad lesson is straightforward. Insider purchases are not equally informative across the cap spectrum, and the lower end of the market, especially below roughly €200 million, is where the signal has the best chance of surviving to T+90. The next step is not to repeat that sentence more loudly. It is to test it properly on a clean event set, sorted into cap quintiles at the filing date, with realistic filters for trade significance and liquidity. The open question, and a useful one, is how much of the apparent small-cap edge remains once you strip out distress, factor exposures, and the cheerful fiction of frictionless execution.
Editorial note, this article was assembled without live web research (Grok unavailable in this generation pass). Evergreen sources are cited above; numerical claims are pulled from our own database snapshot as of 2026-05-17.
Our analysis of small-cap insider buying reveals intriguing insights from a comprehensive backtest involving 220,691 priced trades across 17 markets. The data indicates a mean 90-day return of -1.70% with a win rate of 41.82%, resulting in an annualized Sharpe ratio of -0.08. This suggests that despite the common perception that insider buying is a bullish signal, the actual performance of small-cap stocks following such trades has been underwhelming. The aggregate context further supports this finding, with 227,594 BUY filings yielding the same mean return and Sharpe ratio. These figures highlight the complexities of interpreting insider buying activity, particularly in the small-cap segment, where market dynamics can significantly influence outcomes. It is essential to consider the sample size and time horizon when drawing conclusions from these results.
Last reviewed · 2026-05-18 · By Simon Azoulay · Sources, SEC EDGAR, AMF BDIF, and 28 other regulators.
Who bought, what, how much, when, under which rules: a practical guide to reading one insider filing, from Form 4 codes ...
Antoine Flamarion bought EUR 3.85m of Tikehau Capital on July 16. Read the filing against the private markets backdrop a...
LVMH rose 2.66% on July 16 as luxury steadied, while the latest insider record stayed quiet after March family buys.
Nuvalent’s CEO filed a EUR 22.1m merger-related Form 4 as GSK closed its $124 cash deal. The real story is the oncology ...
Whitestone REIT’s CEO filed a 1.16 million-share sale as the Ares cash deal closes, with retail REITs still trading on r...
ABC Arbitrage’s July 15 board sales came as European markets slipped and the stock sat near 5.06 EUR, with a 7.90 EUR ta...
